Role of tirofiban with dual antiplatelet therapy in patients with STEMI undergoing primary PCI

Türker, Yasin

doi:10.5152/anatoljcardiol.2015.6654

Anatol J Cardiol

2015

DOI: 10.5152/anatoljcardiol.2015.6654

|View full text |Cite

Role of tirofiban with dual antiplatelet therapy in patients with STEMI undergoing primary PCI

Yasin Türker

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Fondaparinux Sodium for Anticoagulant Therapy After Primary Percutaneous Coronary Intervention: A Single-Center Randomized Trial in China

Li,

Zhong,

Luo

et al. 2024

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

In this study, we investigated the safety and efficacy of fondaparinux sodium in post-percutaneous coronary intervention (PCI) anticoagulation therapy for patients with ST-segment elevation myocardial infarction. There are a total of 200 patients with ST segment elevation myocardial infarction underwent PCI and anticoagulation therapy. They were randomly split into experimental (n=108) and control groups (n=92). The experimental group received postoperative fondaparinux sodium (2.5 mg q.d.), while the control group received enoxaparin (4000 IU q12h). We did not use a loading dose for enoxaparin. Bleeding incidence and major adverse cardiovascular/cerebrovascular events (MACCE) were monitored during hospitalization, and at 1, 3, and 6 months post-surgery. The primary endpoints, including bleeding, mortality, and myocardial infarction during hospitalization, were not significant different between the two groups. For secondary endpoints, the incidence of combined endpoint events at 1 month, 3 months, and 6 months following surgery in the experimental group was lower than in the control group (P < 0.05). According to Cox regression analysis, the risk of bleeding in the experimental group was significantly lower than that in the control group (hazard ratios: 0.506, 95% confidence interval (CI): 0.284-0.900) (P=0.020). The risk of mortality in the experimental group was significantly lower than in the control group (hazard ratio: 0.188, 95% CI: 0.040-0.889) (P=0.035). In summary, perioperative use of fondaparinux sodium during PCI in patients with STEMI in this study was associated with a lower risk of bleeding and death compared to enoxaparin use in the absence of loading dose.

show abstract

Fondaparinux Sodium for Anticoagulant Therapy After Primary Percutaneous Coronary Intervention: A Single-Center Randomized Trial in China

Li,

Zhong,

Luo

et al. 2024

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

show abstract

Effect of Pre PCI Antiplatelet Therapy in STEMI Patients Undergoing Primary PCI

Muhammad Idrees Khan,

Muzdalfa Parvez,

Akhtar Zada

et al. 2024

IJBR

View full text Add to dashboard Cite

Objective: To evaluate the effectiveness and safety of pre-percutaneous coronary intervention (PCI) antiplatelet therapy in patients with ST-elevation myocardial infarction (STEMI) undergoing primary PCI, specifically focusing on ST-segment resolution, mortality, and bleeding outcomes. Methodology: A prospective, randomized clinical trial was conducted from January 2023 to December 2023 at Hayatabad Medical Complex, Peshawar, Pakistan. A total of 300 STEMI patients were randomized into two groups: one received pre-PCI antiplatelet therapy, while the control group received standard post-PCI therapy. Outcomes assessed included ST-segment resolution, 30-day mortality, and bleeding events. Statistical analysis was performed using chi-square tests and t-tests to determine differences in outcomes between groups, with significance set at p<0.05. Results: Patients receiving pre-PCI antiplatelet therapy demonstrated a higher rate of ST-segment resolution (74.7%) compared to the control group (71.3%), though this difference was not statistically significant (p=0.603). A non-significant trend toward lower 30-day mortality was observed in the pre-PCI group (11.3% vs. 12.7%, p=0.859). Bleeding events were comparable between groups, with no significant increase in the pre-PCI therapy group (p=0.286). Conclusion: Pre-PCI antiplatelet therapy shows promise in improving reperfusion outcomes without elevating bleeding risk in STEMI patients, suggesting it could be a valuable addition to standard care in similar clinical settings.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Role of tirofiban with dual antiplatelet therapy in patients with STEMI undergoing primary PCI

Cited by 2 publications

References 9 publications

Fondaparinux Sodium for Anticoagulant Therapy After Primary Percutaneous Coronary Intervention: A Single-Center Randomized Trial in China

Fondaparinux Sodium for Anticoagulant Therapy After Primary Percutaneous Coronary Intervention: A Single-Center Randomized Trial in China

Effect of Pre PCI Antiplatelet Therapy in STEMI Patients Undergoing Primary PCI

Contact Info

Product

Resources

About